Drug discovery is becoming increasingly challenging, requiring innovative technologies capable of identifying new drug leads for intractable or “undruggable” targets. Here we discuss how combining surface chemistry and mass spectrometry is opening new avenues to initiate drug discovery for virtually any target.
In this webinar, Dr. Zack Gurard-Levin of Charles River Labs (previously SAMDI Tech, Inc.) will walk you through the benefits of the leading label-free and high-throughput methodology, including eliminating false positive and negative results, multiplexing opportunities and accelerated timelines.
If you are interested in small molecule drug discovery, including for enzyme inhibitors, chemically induced proximity, degraders, RNA binders and more, join us to learn how this flexible technology offers unique solutions and has only begun to scratch the surface of drug discovery research.
